Virologica Sinica

, Volume 28, Issue 2, pp 71–80

Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1


DOI: 10.1007/s12250-013-3313-x

Cite this article as:
Zhu, Z., Prabakaran, P., Chen, W. et al. Virol. Sin. (2013) 28: 71. doi:10.1007/s12250-013-3313-x


More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) — for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.


Antibodies Viruses SARS-CoV Hendra virus Nipah Virus 

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Zhongyu Zhu
    • 1
  • Ponraj Prabakaran
    • 1
    • 2
  • Weizao Chen
    • 1
  • Christopher C. Broder
    • 3
  • Rui Gong
    • 4
  • Dimiter S. Dimitrov
    • 1
  1. 1.Protein Interactions Group, National Cancer InstituteNational Institutes of HealthFrederickUSA
  2. 2.Basic Research ProgramScience Applications International Corporation-Frederick, Inc.FrederickUSA
  3. 3.Department of Microbiology and ImmunologyUniformed Services UniversityBethesdaUSA
  4. 4.Center for Emerging Infectious Diseases, Wuhan Institute of VirologyChinese Academy of SciencesWuhan, HubeiChina

Personalised recommendations